FDA Revises Guide on Demonstrating Drug Effectiveness

FDA has issued a revised draft guidance that updates how sponsors can demonstrate "substantial evidence" of effectiveness for new drugs and biologics, reflecting advances in clinical trial design, real-world evidence, and precision medicine. The document is part of an HHS and FDA initiative (see story) to help keep drug development thriving in the U.S.

The draft, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, revises a 2019 draft and is intended to replace FDA's longstanding 1998 guidance on clinical evidence of effectiveness. The agency said the update is designed to clarify how sponsors may satisfy statutory approval requirements using a variety of evidence-generating approaches.

Central to the guidance is FDA's position that, in some cases, a single adequate and well-controlled clinical investigation combined with confirmatory evidence may be sufficient to establish effectiveness. The agency noted that advances in scientific understanding and the availability of high-quality data have expanded the ways sponsors can generate persuasive evidence of treatment benefit.

The draft outlines factors that affect the strength of evidence, including trial design, conduct, statistical analysis, and the overall development program. FDA emphasizes that evidence should be evaluated based on its totality rather than a rigid formula.

The agency discusses a range of study designs that may support approval, including randomized controlled trials, non-inferiority studies, externally controlled trials, and, in certain circumstances, observational studies. The guidance also highlights the growing role of surrogate endpoints and real-world evidence, while stressing that sponsors must provide adequate scientific justification for their use.

FDA further states that regulatory flexibility may be warranted in situations such as rare diseases, serious conditions with unmet medical needs, or when conventional trials are infeasible. In those settings, the agency may consider alternative trial designs, different forms of confirmatory evidence, and other approaches tailored to the clinical context.

The guidance reiterates that demonstrating effectiveness alone is not sufficient for approval. Sponsors must also provide adequate safety data and support a favorable benefit-risk assessment. FDA encourages companies to discuss their proposed evidence-generation strategies with the agency early in development, preferably no later than the end-of-Phase II stage.